Sting-challenge demonstrated tolerance in patients undergoing reduced-dose Jumper ant venom-specific immunotherapy: Validating new center approach in adult and children.

Allergy to the venom of Australian native Hymenoptera insect species Myrmecia pilosula (Jack Jumper ant [JJA]) is an important cause of anaphylaxis in south-eastern Australia. Sensitization has been estimated at up to 3% of the population in endemic areas.1 Venom-specific immunotherapy (VIT) to Hymenoptera species such as honey bee and wasp is well established for inducing allergic tolerance, reducing the risk of allergic symptoms, including life-threatening anaphylaxis.2 This involves structured intermittent dosing with the specific allergen to induce an immunologic tolerance over several months.